Objective The use of lymph node sampling during staging procedures in clinical early-stage mucinous ovarian carcinoma (MOC) is an ongoing matter of debate. Furthermore, the incidence of lymph node metastases (LNM) in MOC in relation to tumour grade (G) is unknown. We aimed to determine the incidence of LNM in clinical early-stage MOC per tumour grade.
Introduction
Mucinous ovarian carcinoma (MOC) is a rare ovarian malignancy with an estimated incidence of 3-5% of all epithelial ovarian carcinomas (EOC). 1, 2 Patients with MOC often present with a large unilateral ovarian mass without metastasised disease. In these patients, prognosis is relatively good with a 5-year disease-free survival of 90.8%. 3 Another rare ovarian malignancy that has been identified as a separate entity in the revised World Health Organization (WHO) Classification, is seromucinous ovarian carcinoma. 4 This histotype, previously classified as endocervical-type or M€ ullerian mucinous carcinomas, is a morphological admixture of serous, mucinous and endometrioid cell types. Patients with a seromucinous carcinoma are usually diagnosed with disease confined to the ovary. Therefore, their prognosis is relatively good. 5 In patients with clinical early-stage EOC, a staging procedure is recommended. During staging procedures, bilateral salpingo-oophorectomy, hysterectomy and (infracolic) omentectomy are performed and peritoneal biopsies are taken. Furthermore, national guidelines in the Netherlands advise sampling of at least ten lymph nodes from the paraaortic and pelvic regions. 6 In many patients with MOC, this procedure is performed; although, several studies have demonstrated a low incidence of lymph node metastases (LNM) of 0.0-6.7%. 7, 8 Apart from histological classification, EOC can be categorised by tumour grade. Grading systems are primarily developed for serous and endometrioid carcinomas, but are less applicable to MOC because of their overall low-grade architectural appearance. No histological grading system has been universally accepted for MOC. As a result, most pathologists use the Silverberg-Shimizu criteria 9 for MOC, in the absence of a better alternative. Histological grading has an important prognostic value, but can also influence the choice of treatment. In serous and endometrioid EOC, low-grade tumours have a more indolent behaviour with a more favourable progression-free and overall survival, compared with high-grade tumours. 10, 11 It can be expected that patients with low-grade tumours demonstrate a much lower incidence of LNM compared with high-grade tumours. Indeed, Kleppe et al. 7 demonstrated that 4.0% of serous and endometrioid EOC patients with clinical earlystage of grade 1 (G1) tumours had LNM, compared with 20.0% in G3 tumours.
In MOC, the correlation between tumour grade and incidence of LNM is unknown. We hypothesised that LNM in clinical early-stage G1 MOC have a low incidence or are non-existent. Our objective was to evaluate the need for a staging lymph node sampling in patients with clinical early-stage MOC of different tumour grades.
Methods

Patient selection
The Dutch Pathology Registry (PALGA), 12 a nationwide network and registry that has recorded all histopathology and cytopathology since 1991, was searched after approval from the privacy committee of PALGA. All patients diagnosed with MOC between January 2002 and December 2012 were selected based on pathology reports comprising the terms: 'ovary' OR 'tube', AND 'mucinous carcinoma' OR 'mucinous adenocarcinoma' OR 'mucin'. The pathology reports of the surgical procedures, as well as pathology history and life-long pathology follow up of at least 24 months, were obtained. A database of 18 465 pathology reports from a total of 1828 patients was built. For privacy reasons, all patients from the registry are itemised by a specific PALGA-code. Under this code, excerpts containing anonymised pathology reports, dates of tissue collection and age at time of tissue collection are registered. Researchers had no access to patient names or other information that could lead to identification of the patient. Therefore, no patient informed consent and no additional approval of the Institutional Review Board were required.
All excerpts were initially scrutinised by the principal author (JOAMB). Ovarian tumours with a histological diagnosis other than MOC, tumours with insufficient criteria of invasive malignancy (i.e. borderline tumour, carcinoma in situ or intraepithelial carcinoma), ovarian metastases of tumours from a different primary origin and reports with inconclusive data were excluded (for exclusion criteria, see Figure 1 ). In case of ambiguity concerning diagnosis, reports were discussed with a dedicated gynaecological pathologist (KKV). Patients with clinical early-stage disease underwent staging procedures and had either clinical FIGO stage I or II disease. Furthermore, surgical-pathological FIGO stage was determined for each tumour.
No central review of histopathology was performed in our study, because in the Netherlands all patients with EOC are treated in a tertiary referral hospital where histopathological review by a dedicated gynaecological pathologist is standard clinical practice. Of each case, the primary diagnosis and official review of histopathology performed in a tertiary referral hospital, were documented.
Seromucinous, endocervical-type mucinous and M€ ullerian mucinous carcinomas as well as mixed cell types with a mixed endometrioid or serous and mucinous aspect were collectively grouped as seromucinous carcinoma, according to the new WHO guidelines. 4 Information including clinical data, surgery reports, radiology reports and follow-up data of all patients with LNM was retrieved from the hospital files via an intermediate procedure of PALGA. Anonymised clinical data and patient characteristics were requested from the treating physicians to maintain absolute privacy of the patient. No histology was required for this study. Therefore, no informed consent was needed to collect these additional clinical data.
Statistical analyses
Statistical analyses were performed using IBM SPSS (Statistical Package for the Social Sciences) version 22.0 (SPSS Inc., Chicago, IL, USA). The two-sided chi-square test was used to test for associations between categorical variables and the Student's t test was used to evaluate differences in normally distributed, continuous variables. The incidence rate of LNM in patients with MOC was calculated by dividing the patients with metastases by the total number of patients. Additionally, to gain insight into changes in incidence of MOC over the study period, incidence rates per year and per 100 000 women were calculated using the average yearly female population numbers in the Netherlands. 13 Changes in the incidence rates over time were assessed using a logistic regression model. Kaplan-Meier survival curves were generated for clinical early-stage disease patients who received staging procedures with and without lymph node sampling to determine disease-free survival (DFS). DFS was defined as the time elapsed between the date of primary diagnosis and the date of histological or cytological confirmation of local, regional or distant recurrent disease. Patients who had no recurrent disease or who died before recurrence occurred (confirmed by post-mortem examination) by the time of their last pathology report, were right-censored in the survival curves. DFS was compared between these groups using Log Rank (Mantel-Cox) tests.
Results
Patients
From a search of PALGA, a total of 1828 patients with possible MOC were identified between January 2002 and December 2012. After detailed examination of the reports from the PALGA registry, 803 patients were excluded for reasons such as ovarian metastases of a different primary origin or lack of malignancy, leaving 1025 patients eligible for our study ( Figure 1 ). Of these 1025, patients diagnosed with a pure MOC totalled 915 individuals and 110 patients had a seromucinous carcinoma.
Mucinous ovarian cancer
Clinical characteristics of the patients with MOC are shown in Table 1 . The majority of patients were diagnosed with G1 or G2 MOC and 74.9% of these patients had FIGO stage I. Patients with G3 MOC often had metastasised disease at time of diagnosis (70.5%). In the total group of patients with MOC, 17 (1.9%) patients were diagnosed with LNM. In nine patients, LNM were removed during cytoreductive surgery. Supradiaphragmatic LNM were not found. During the 11 years considered in this study, the incidence rates of MOC per 100 000 Dutch women per year declined ( Figure 2 ).
To understand whether tumour grade influences the chance of LNM in clinical early-stage MOC, we focused on patients who received staging procedures. Complete staging procedures including lymph node sampling, were performed in 426 patients, revealing eight patients with LNM (Table 2) . Patients with G1 and G2 disease showed significantly less LNM compared with G3 MOC (G1 versus G3 P = 0.03; G2 versus G3 P = 0.01). The exact number of Figure 1 . Flowchart of patient selection. A database of 1828 patients with supposed MOC was built. FIGO stage was determined based on pathology reports; 915 patients with MOC with evident advanced disease were separated from patients who underwent staging procedures. Patients undergoing staging procedures for clinical early-stage MOC were categorised into a group who had lymph node sampling and those who had staging procedures without lymph node sampling.
lymph nodes removed during staging procedures was known for 58% of the patients. Median number of resected lymph nodes was 12 (interquartile range 8-18 lymph nodes).
To examine whether the patients with LNM had apparent evidence of lymphadenopathy on preoperative radiological imaging or during the staging procedures, we investigated the clinical data of these patients (Table 2) . Interestingly, in five out of eight (62.3%) patients with metastases identified during staging lymph node sampling, enlarged lymph nodes were already present on radiological examination or enlarged by palpation during the staging procedures. Hence, in patients with G1 MOC without clinical suspicion of metastatic disease, only two (1.1%; 95% CI 0.13-3.75%) patients had unexpected LNM. Patients with G2 MOC without signs of clinical metastases had no LNM found with staging procedures (95% CI 0-0.03%). However, 4.5% (95% CI 0.12-22.84%) of patients with G3 MOC, without preoperative evidence of metastatic disease in the lymph nodes were shown to have (microscopic) lymphadenopathy.
Next, to evaluate whether tumour grade is correlated with DFS, Kaplan-Meier survival analyses were performed for all patients with pathological FIGO stage I MOC (Figure 3A) . A more favourable DFS was observed for patients with G1 and G2 MOC than for those with G3 MOC (P < 0.001). In 6.6% of all patients with pathological FIGO stage I MOC, recurrent disease was diagnosed after a median DFS of 27 months (95% CI 17.4-45.7), whereas 9.3% of patients with G2 MOC and 34.6% of patients with G3 MOC developed recurrent disease.
Lastly, to examine whether lymph node sampling is associated with a survival benefit, DFS of patients who underwent lymph node sampling was compared with DFS of patients who had incomplete staging procedures. DFS of clinical early-stage MOC patients without lymph node sampling and patients who underwent staging with lymph node sampling were comparable within each tumour grade ( Figure 3B ). These findings for G1 and G2 tumours were reasonably expected based on the low incidence of LNM seen in these tumours. Although the number of patients with G3 MOC that underwent staging procedures was small, no DFS benefit was seen in those who had lymph node sampling (P = 0.29). Taken together, these results demonstrate that performing lymph node sampling in the absence of clinical evidence of metastases does not favour DFS. Average yearly female population numbers were retrieved from Statistics Netherlands. 13 With logistic regression analyses the yearly probabilities of MOC were calculated, demonstrating a decline in diagnosis over the period 2002-12 (OR 0.96 per year; P < 0.001). The predicted incidence curve for patients with MOC is depicted. For seromucinous ovarian carcinoma, no significant change in the incidence over time was observed (P = 0.89).
Seromucinous ovarian cancer
Of all the patients who presented with EOC between January 2002 and December 2012, 110 patients were diagnosed with a seromucinous (or endocervical-type mucinous) carcinoma ( Figure 1 ). During this time, the incidence of seromucinous carcinoma was stable (Figure 2) . The characteristics of these patients are presented in Table 3 . The mean age of this cohort was 56.1 years and there was no difference in age when the group was subdivided by tumour grade. Most patients (39.1%) were diagnosed with G1 disease. Among the entire seromucinous carcinoma cohort, five (4.5%) patients had LNM. Strikingly, none of these LNM were found in patients with G1 seromucinous carcinoma. In three (60%) patients with lymphadenopathy, axillar or supraclavicular LNM were found, which was not found in any of the MOC patients. Staging lymph node sampling was performed in 46 out of 110 patients, but did not reveal any additional LNM (Table 3 ). Median number of removed lymph nodes during lymph node sampling was 13 (interquartile range 9-29).
In patients with clinical early-stage disease with G1, G2 and G3 seromucinous carcinomas, recurrent disease occurred in four (12.5%), three (15.8%) and two (50%) patients, respectively (P = 0.16). In conclusion, LNM in G1 seromucinous carcinoma could not be found. However, the number of patients that received lymph node samplings for seromucinous carcinoma in the present study is too small to draw solid conclusions from these results. Tumour grade was not specified in 99 patients who underwent sampling and no LNM were found in these patients. *Pearson chi-square test.
Discussion
Main findings
Our study shows that LNM in clinical early-stage G1 or G2 MOC are rare. In the absence of nodal enlargement on radiological examination or on palpation during staging procedures, only 0.7% of the patients with G1 and G2 MOC had LNM. No DFS benefit from lymph node sampling was observed in these patients with clinical early-stage MOC. Although the number of patients with G3 MOC that received staging procedures was small, no DFS benefit was observed in those who underwent sampling. This is the first study that reports LNM in MOC per tumour grade. Our study demonstrates that G3 MOC is associated with a higher incidence of LNM discovered during staging, than G1 and G2 MOC. These findings suggest that G3 MOC has a more progressive course of disease. Patients with G1 and G2 MOC presented with a similar course of disease, based on FIGO stages at diagnosis, incidence of LNM and DFS. This tumour grade-specific behaviour can also be seen in other EOC subtypes, such as low-grade and high-grade serous carcinoma. 14, 15 Therefore, different MOC tumour grades should not be regarded as one group. The differences in clinical behaviour may be explained by differences in genetic drivers. Several mutated genes have been identified for MOC, including KRAS, BRAF, CDKN2A and TP53 genes. [16] [17] [18] [19] Recently, Ryland et al. 16 investigated the variances of genomic landscapes between tumour grades of MOC, but demonstrating differences between tumour grades was hindered by the heterogeneity of MOC and the small study populations.
Lymph node sampling in early-stage EOC has been the subject of debate in the last two decades. Previously, studies demonstrated a survival benefit for patients with early-stage EOC undergoing complete staging procedures. 20, 21 However, in these studies, different histotypes were taken together and none investigated MOC with focus on its separate tumour grades. Despite clear guidelines in the Netherlands concerning staging procedures, in our study only 65% of patients with early-stage disease underwent lymph node sampling. The exact reasons for omitting this procedure remain unknown, but age of patients, tumour grade, intra-operative suspicion of extra-nodal metastases, increasing knowledge on staging in MOC during the study period, or local differences in hospital guidelines might have influenced this decision. Certainly, this number reflects the ongoing ambiguity among gynaecologists concerning the necessity to perform lymph node sampling in these patients.
With regard to seromucinous carcinomas, only a few studies with small patient cohorts investigated the behaviour and morphology. 5, 22, 23 This is the first study reporting data of a large cohort with 110 seromucinous carcinomas. LNM were more common than in MOC, but did not occur in G1 seromucinous carcinomas. Furthermore, 60% of patients with LNM had tumour involvement of axillary or supraclavicular nodes, which did not occur in the MOC group. Extra-abdominal LNM of high-grade serous carcinoma at time of presentation has been described Table 3 . Characteristics of 110 patients with seromucinous ovarian carcinoma per tumour grade
Variable
All Seromucinous carcinomas n = 110 (%) previously. 24 This suggests that G2 and G3 seromucinous carcinomas resemble a metastasis pattern similar to that of high-grade serous carcinomas. Future studies must be performed to demonstrate possible similarities in genetic drivers of these tumours. Interestingly, no LNM were found with staging sampling for seromucinous carcinoma. However, the number of patients that received sampling was small. Therefore, no robust conclusions can be drawn for patients with early-stage seromucinous carcinoma. These findings may be the basis for future studies in which multicentre collaboration is necessary to achieve sufficient study populations. For all tumour grades, recurrent disease occurred more frequently in patients with seromucinous carcinoma than in patients with MOC. These results are consistent with the new WHO guidelines, 4 in which seromucinous carcinomas are included as a separate entity, rather than as a variant of MOC.
Strengths and limitations
The main limitation of our study is the incomplete information on lymph node status in some patients. National guidelines recommend sampling of at least ten lymph nodes during staging procedures, based on studies that demonstrated no survival difference compared with systematic lymphadenectomy. [25] [26] [27] [28] The number of resected lymph nodes was known in only 58% of patients. With a median of 12 resected lymph nodes in those patients, we can assume that the incidence of LNM is accurate, but not sufficient in all patients. Furthermore, DFS was equal for groups with and without sampling. The differences in DFS between different tumour grades of MOC are unlikely to change because of this.
Defining tumour grade in MOC is controversial, as the current classification system is suboptimal for MOC. For all ovarian carcinoma histotypes, defining tumour grade has prognostic and therapeutic implications. With the use of Silverberg criteria, a G3 MOC is well distinguishable, but morphological distinction between G1 and G2 MOC may be difficult. Our results implicate that possibly a two-tier grading system would suffice, categorising G1 and G2 as low-grade tumours and G3 as high-grade tumours. In 75% of MOC, tumour grade was known and demonstrated clear prognostic differences between low-grade and high-grade MOC, confirming that tumour grade can be reliably established.
The incidence of recurrent disease was based on histopathological examination. This might have led to an underestimation of the number of recurrences. An obvious recurrence diagnosed with clinical or radiological examination might, in some cases, have been treated without histopathological confirmation. In our study, all data were collected retrospectively. Validation of the results with prospective patient cohorts would be ideal, yet difficult because of the rarity of MOC and the low incidence of LNM.
Interpretation
Our results were based on pathology and radiology reports and no central revision was performed.
In the Netherlands, staging procedures are performed in tertiary hospitals, where histopathological revision by a gynaecology-oriented pathologist is standard care. However, in 24.3% of all MOC, tumour grade was unspecified in the pathology reports. Our results emphasise the importance of precise histopathological designation with grading specification and should therefore be performed by a gynaecology-oriented pathologist.
We had no information concerning administration of adjuvant chemotherapy. Although for G3 MOC or nonoptimally staged patients, adjuvant chemotherapy may have been considered, it is unlikely that completely staged patients with FIGO stage I G1 or G2 MOC have received chemotherapy. Moreover, the poor chemosensitivity of MOC indicates that administration of chemotherapy may have only a minimal effect on the outcome of early-stage MOC. 29, 30 Nevertheless, for G3 MOC patients who received either complete or incomplete staging, with or without adjuvant chemotherapy, overall prognosis is poor.
Conclusion
In conclusion, although no optimal grading system exists for MOC, our results imply that a binary system will reflect prognostic differences between low-grade and high-grade tumours. Lymph node sampling can be omitted in clinical early-stage low-grade MOC. The benefits of sampling in clinical early-stage high-grade MOC are unclear. Generally, it is possible to distinguish a low-grade from a high-grade tumour, even on frozen section, 31, 32 though in the case of unknown histology before staging or difficulty to specify tumour grade on frozen section, it may be necessary to perform lymph node sampling. Omitting sampling could have positive effects on surgery-related complications, blood loss and operating time. 33 However, an experienced surgeon is a prerequisite for optimal assessment of nodal enlargement during surgery and the subsequent decision on whether sampling should be performed.
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